WO2021184094A1 - Aditivo para detoxificação - Google Patents

Aditivo para detoxificação Download PDF

Info

Publication number
WO2021184094A1
WO2021184094A1 PCT/BR2021/050051 BR2021050051W WO2021184094A1 WO 2021184094 A1 WO2021184094 A1 WO 2021184094A1 BR 2021050051 W BR2021050051 W BR 2021050051W WO 2021184094 A1 WO2021184094 A1 WO 2021184094A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
mcg
additive
detoxification
pycnogenol
Prior art date
Application number
PCT/BR2021/050051
Other languages
English (en)
French (fr)
Inventor
Wellington Nascimbeni SILVA
Original Assignee
Silva Wellington Nascimbeni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silva Wellington Nascimbeni filed Critical Silva Wellington Nascimbeni
Priority to US17/912,660 priority Critical patent/US20230139771A1/en
Priority to EP21770418.8A priority patent/EP4122454A4/en
Priority to MX2022011657A priority patent/MX2022011657A/es
Publication of WO2021184094A1 publication Critical patent/WO2021184094A1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system

Definitions

  • the present patent application for Privilege of Invention refers to an additive, whose function is to increase immunity, prevent various diseases, increase the detoxification of the organism.
  • the chemical composition in question comprises: 60 mcg of vitamin A; 4.5 mg vitamin C; 1 mg vitamin E; 3.4 mcg of selenium; 0.5 mg copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyne Q10; 5 mg of pycnogenol; 0.13 mg vitamin B2; 1.6 mg vitamin B3; 0.13 mg of VitaminB6; 24 mcg of folic acid; 0.24 mcg of vitamin B 12; 2 mg of Glutathione; 100mg of Leucine; 20 mg of Isoleucine; 20 mg of valine; 50mg of Glycine; 50 mg of taurine; 300 mg Glutamine; 60 mg of acetylcysteine; 50 mg Cysteine; 100mg Methionine; 0.5 mg Vitamin B5; 2 mg lycopene and 4 mg resveratrol.
  • This product is based on the principle of detoxification of the body, with minerals, vitamins and other compounds present in its formulation that are necessary for the detoxification process to occur in the body, that is, they all have the same function in the formula, that of help promote detoxification, an action that occurs by the activity of all components together.
  • the detoxification process is a chain of chemical reactions that occur in the body in order to make foreign substances more hydrophilic to the body and thus more easily eliminated from the body. 7.
  • the purpose of this patent application is the development of a new food formula that will be able to obtain the result described for the purpose of this additive, which is to increase the body's detoxification process.
  • Manufacturing will be done by combining twenty-seven components: 60 mcg of vitamin A; 4.5 mg vitamin C; 1 mg vitamin E; 3.4 mcg of selenium; 0.5 mg copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyne Q10; 5 mg of pycnogenol; 0.13 mg vitamin B2; 1.6 mg vitamin B3; 0.13 mg of VitaminB6; 24 mcg of folic acid; 0.24 mcg of vitamin B12; 2 mg of Glutathione; 100mg of Leucine; 20 mg of Isoleucine; 20 mg of valine; 50mg of Glycine; 50 mg of taurine; 300 mg Glutamine; 60 mg of acetylcysteine; 50 mg Cysteine; 100mg Methionine; 0.5 mg Vitamin B5; 2 mg lycopene and 4 mg resveratrol.
  • said chemical composition represents a solution capable of obtaining concentration with vitamins, minerals, amino acids and bioactive compounds.
  • the technical and functional advantage is that it is unique because it brings together all vitamins, minerals and other substances that act in the body's detoxification process, helping in a healthier life.
  • As an economic and functional advantage we can mention that it will not be necessary to ingest a large amount of food for the body to start performing the detoxification process more efficiently, which would save money and energy in the body.
  • composition was created, more precisely to a combination of twenty-seven components: 60 mcg of vitamin A; 4.5 mg vitamin C; 1 mg vitamin E; 3.4 mcg of selenium; 0.5 mg copper; 0.7 mg of zinc; 0.23 mg of manganese; 3 mg of coenzyne Q10; 5 mg of pycnogenol; 0.13 mg vitamin B2; 1.6 mg vitamin B3; 0.13 mg of VitaminB6; 24 mcg of folic acid; 0.24 mcg of vitamin B 12; 2 mg of Glutathione; 100mg of Leucine; 20 mg of Isoleucine; 20 mg of valine; 50mg of Glycine; 50 mg of taurine; 300 mg Glutamine; 60 mg of acetylcysteine; 50 mg Cysteine; 100mg Methionine; 0.5 mg Vitamin B5; 2 mg of lycopene and 4 mg of resveratrol, forming a compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

O presente pedido de patente de privilégio de invenção trata essencialmente de um aditivo cuja função consiste em aumentar a imunidade, prevenir diversas doenças e aumentar a detoxificação do organismo. O aditivo é composto por: 60 mcg de vitamina A; 4,5 mg de vitamina C; 1 mg de vitamina E; 3,4 mcg de selênio; 0,5 mg de cobre; 0,7 mg de zinco; 0,23 mg de manganês; 3 mg de coenzima Q10; 5 mg de picnogenol; 0,13 mg de vitamina B2; 1,6 mg de vitamina B3; 0,13 mg de vitamina B6; 24 mcg de ácido fólico; 0,24 mcg de vitamina B12; 2 mg de glutationa; 100mg de leucina; 20 mg de isoleucina; 20 mg de valina; 50 mg de glicina; 50 mg de taurina; 300 mg de glutamina; 60 mg de acetilcisteina; 50 mg de cysteina; 100 mg de metionina; 0,5 mg de vitamina B5; 2 mg de licopeno; e 4 mg de resveratrol.

Description

ADITIVO PARA DETOXIFICAÇÃO
INTRODUÇÃO:
1. Refere-se o presente pedido de patente de Privilégio de Invenção, a um aditivo, cuja função consiste em aumentar a imunidade, prevenir diversas doenças, aumentar a detoxificação do organismo.
2. O referido produto, cuja proteção será reivindicada neste relatório, foi desenvolvido com o intuito de suprir deficiências, amenizar dificuldades e solucionar problemas até então encontrados pelos usuários do setor, mais precisamente, setores da Bioquímica e farmacêutico.
CARACTERÍSTICAS:
3. A composição química em questão, apresentado por meio deste relatório, é composto por: 60 mcg de vitamina A; 4,5 mg de vitamina C; 1 mg vitamina E; 3,4 mcg de selênio; 0,5 mg de cobre; 0,7 mg de zinco; 0,23 mg de manganês; 3 mg de coenzina Q10; 5 mg de picnogenol; 0,13 mg de vitamina B2; 1,6 mg de vitamina B3; 0,13 mg de VitaminaBó; 24 mcg de ácido fólico; 0,24 mcg de vitamina B 12; 2 mg de Glutationa; lOOmg de Leucina; 20 mg de Isoleucina; 20 mg de valina; 50 mg de Glicina; 50 mg de taurina; 300 mg de Glutamina; 60 mg de acetilcisteina; 50 mg de Cysteina; 100 mg de Metionina; 0,5 mg de Vitamina B5; 2 mg de licopeno e 4 mg de resveratrol.
FUNCIONALIDADE:
4. Inicialmente a referida composição química, descrita por meio deste relatório, será utilizado nos setores da Bioquímica e farmacêutico.
5. Esse produto é baseado no princípio de detoxificação do organismo, com minerais, vitaminas e outros compostos presentes na sua formulação que são necessários para que o processo de detoxificação ocorra no organismo, ou seja, todos tem a mesma função na formula, o de ajudar a promover a detoxificação, ação essa que ocorre pela atividade de todos componentes em conjunto.
6. Irá atuar no processo de detoxificação do organismo, ou seja, ajudando a eliminar toxinas do organismo. O processo de detoxificação e uma cadeia de reações químicas que ocorrem no organismo de modo a tornar substancias estranhas pro corpo mais hidrofílicas sendo dessa forma mais facilmente eliminadas do corpo. 7. O objetivo deste pedido de patente, é o desenvolvimento de uma nova fórmula alimentícia que será capaz de obtermos o resultado descrito para a finalidade desse aditivo que é aumentar o processo de detoxificação do organismo.
8. Em pesquisa realizada nas bases de dados de produção médica/científica não existe resultado sobre o que está sendo proposto.
9. A fabricação será feita pela combinação de vinte e sete componentes: 60 mcg de vitamina A; 4,5 mg de vitamina C; 1 mg vitamina E; 3,4 mcg de selênio; 0,5 mg de cobre; 0,7 mg de zinco; 0,23 mg de manganês; 3 mg de coenzina Q10; 5 mg de picnogenol; 0,13 mg de vitamina B2; 1,6 mg de vitamina B3; 0,13 mg de VitaminaBó; 24 mcg de ácido fólico; 0,24 mcg de vitamina B12; 2 mg de Glutationa; lOOmg de Leucina; 20 mg de Isoleucina; 20 mg de valina; 50 mg de Glicina; 50 mg de taurina; 300 mg de Glutamina; 60 mg de acetilcisteina; 50 mg de Cysteina; 100 mg de Metionina; 0,5 mg de Vitamina B5; 2 mg de licopeno e 4 mg de resveratrol.
INOVAÇÃO:
10. Em termos gerais, a referida composição química representa uma solução capaz de obtermos a concentração com vitaminas, minerais, aminoácidos e compostos bioativos.
11. A vantagem técnica e funcional é que ele é único pois reuni todas vitaminas, minerais e outras substancias que atuam no processo de detoxificação do organismo, ajudando numa vida mais saudável. Como vantagem económica e também funcional podemos citar que não será necessário a ingestão de uma grande quantidade de alimento para que o organismo comece a realizar o processo de detoxificação de forma mais eficiente, o que economizaria dinheiro e energia no corpo.
DESCRIÇÃO DO ESTADO DA TÉCNICA:
12. Durante o desenvolvimento da referida composição química, foram realizadas inúmeras pesquisas para identificar a existência de eventuais anterioridades ou composições afins. Tais levantamentos, contudo, não apontaram a existência de nenhuma outra composição com as mesmas características técnicas preponderantes ou funcionais.
13. Diante dessa necessidade e oportunidade comercial, criou-se a referida composição, mais precisamente a uma combinação vinte e sete componentes: 60 mcg de vitamina A; 4,5 mg de vitamina C; 1 mg vitamina E; 3,4 mcg de selênio; 0,5 mg de cobre; 0,7 mg de zinco; 0,23 mg de manganês; 3 mg de coenzina Q10; 5 mg de picnogenol; 0,13 mg de vitamina B2; 1,6 mg de vitamina B3; 0,13 mg de VitaminaBó; 24 mcg de ácido fólico; 0,24 mcg de vitamina B 12; 2 mg de Glutationa; lOOmg de Leucina; 20 mg de Isoleucina; 20 mg de valina; 50 mg de Glicina; 50 mg de taurina; 300 mg de Glutamina; 60 mg de acetilcisteina; 50 mg de Cysteina; 100 mg de Metionina; 0,5 mg de Vitamina B5; 2 mg de licopeno e 4 mg de resveratrol, formando um composto em uma diluição especifica para obter-se o efeito desejado.
14. Logo, em conformidade com o artigo 8o da Lei da Propriedade Industrial n° 9.279/96 e por todos os aspectos apresentados neste relatório, o objeto do presente pedido de patente se faz merecedor da proteção como Privilégio de Invenção, que ora se pleiteia.

Claims

REIVINDICAÇÃO
1. ADITIVO PARA DETOXIFICAÇÃO - Trata-se de um aditivo, para aumentar a imunidade, prevenir diversas doenças, aumentar a detoxificação do organismo, caracterizado pelo fato de compreender: 60 mcg de vitamina A; 4,5 mg de vitamina C; 1 mg vitamina E; 3,4 mcg de selênio; 0,5 mg de cobre; 0,7 mg de zinco; 0,23 mg de manganês; 3 mg de coenzina Q10; 5 mg de picnogenol; 0,13 mg de vitamina B2; 1,6 mg de vitamina B3; 0,13 mg de VitaminaBó; 24 mcg de ácido fólico; 0,24 mcg de vitamina B12; 2 mg de Glutationa; lOOmg de Leucina; 20 mg de Isoleucina; 20 mg de valina; 50 mg de Glicina; 50 mg de taurina; 300 mg de Glutamina; 60 mg de acetilcisteina; 50 mg de Cysteina; 100 mg de Metionina; 0,5 mg de Vitamina B5; 2 mg de licopeno e 4 mg de resveratrol.
PCT/BR2021/050051 2020-03-20 2021-02-04 Aditivo para detoxificação WO2021184094A1 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/912,660 US20230139771A1 (en) 2020-03-20 2021-02-04 Additive for Detoxification
EP21770418.8A EP4122454A4 (en) 2020-03-20 2021-02-04 DETOXIFICATION SUPPLEMENT
MX2022011657A MX2022011657A (es) 2020-03-20 2021-02-04 Aditivo para detoxificacion.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102020005629A BR102020005629A2 (pt) 2020-03-20 2020-03-20 aditivo para detoxificação
BR1020200056298 2020-03-20

Publications (1)

Publication Number Publication Date
WO2021184094A1 true WO2021184094A1 (pt) 2021-09-23

Family

ID=76206756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2021/050051 WO2021184094A1 (pt) 2020-03-20 2021-02-04 Aditivo para detoxificação

Country Status (5)

Country Link
US (1) US20230139771A1 (pt)
EP (1) EP4122454A4 (pt)
BR (1) BR102020005629A2 (pt)
MX (1) MX2022011657A (pt)
WO (1) WO2021184094A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554029A (zh) * 2022-11-07 2023-01-03 佛山市顺德区州福慈鑫无纺布有限公司 一种卫生巾辅酶q10生产工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US8747915B1 (en) * 2011-09-14 2014-06-10 Vincent C. Giampapa Dietary supplement system for multifunctional anti-aging management and method of use
US20190069585A1 (en) * 2017-09-01 2019-03-07 Gerald Haase Compositions of micronutrients and phytochemicals for optimal human health

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Active principles for internal use", PH PHARMACUS, 1 January 2017 (2017-01-01), XP055857553, Retrieved from the Internet <URL:http://www.weblandia.com.br/pharmacus/index.php/produtos/principios-ativos/principios-ativos-de-uso-interno> [retrieved on 20211103] *
ANONYMOUS: "Associated vitamins commonly used adults", MEDICINANET, 11 February 2015 (2015-02-11), XP055857557, Retrieved from the Internet <URL:https://www.medicinanet.com.br/conteudos/medicamentos/709/vitaminas_associadas_de_uso_geral_adultos.htm> [retrieved on 20211103] *
ANONYMOUS: "Catalogo de medicamentos - Homeopatia Floral Manipulação", DE FARIA E PINHO, 1 May 2019 (2019-05-01), XP055857548, [retrieved on 20211103] *
ANONYMOUS: "Relatório de Analise das Contribuições da CP", ANVISA, 1 June 2018 (2018-06-01), XP055857544, Retrieved from the Internet <URL:http://antigo.anvisa.gov.br/documents/10181/3898888/Relatório+de+Análise+de+Contribuições+-+CP+457-2017/1de3eb36-b152-4d3d-9411-5d2b5ac68290> [retrieved on 20211103] *
See also references of EP4122454A4 *
SIMONI NATALIA KOREN, ELISEU VERLY JUNIOR, KAROLINE HONORATO BRUNACIO, ÁGATHA NOGUEIRA PREVIDELLI, DIRCE MARIA LOBO MARCHIONI, REG: "Tabela nutricional de suplementos para uso em inqueritos dieteticos. Sao Paulo: Faculdade de Saude Publica da USP", UNIVERSIDADE DE SÃO PAULO, MADRID, 1 January 2013 (2013-01-01), Madrid, XP055857539, [retrieved on 20211103] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554029A (zh) * 2022-11-07 2023-01-03 佛山市顺德区州福慈鑫无纺布有限公司 一种卫生巾辅酶q10生产工艺

Also Published As

Publication number Publication date
EP4122454A4 (en) 2024-04-03
MX2022011657A (es) 2022-10-13
US20230139771A1 (en) 2023-05-04
BR102020005629A2 (pt) 2021-05-18
EP4122454A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
Pushpakumar et al. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide
Zhao et al. Hydrogen sulfide (H 2 S) releasing agents: chemistry and biological applications
Zheng et al. Hydrogen sulfide prodrugs—a review
Bauchart-Thevret et al. Intestinal metabolism of sulfur amino acids
Predmore et al. Hydrogen sulfide in biochemistry and medicine
CY1113988T1 (el) Συνδυαστικο σκευασμα για τη βελτιωση της ποιοτητας του σπερματος
WO2021184094A1 (pt) Aditivo para detoxificação
BR112019004468A2 (pt) estimulantes de sgc
BR112015002309A2 (pt) formulação de múltiplos componentes para aprimorar a função neurológica
Martín-Venegas et al. The methionine precursor DL-2-hydroxy-(4-methylthio) butanoic acid protects intestinal epithelial barrier function
BRPI0412059A (pt) método para a preparação de formulação de liberação controlada
BR112018013349A2 (pt) composição adesiva, método de preparação de uma composição adesiva, e produto adesivo
JP2017507973A5 (pt)
Wu et al. Polymer nanocomposites enhance S-nitrosoglutathione intestinal absorption and promote the formation of releasable nitric oxide stores in rat aorta
BR112012022727A8 (pt) Uso de um ou mais agentes quelantes, composição nutricional, e métodos para prover nutricição a uma pessoa em necessidade da mesma
RU2011129617A (ru) Кормовая композиция, содержащая антиоксидант, предназначенная для усиления противовирусного иммунитета у животных-компаньонов
CY1120820T1 (el) Νεα συνθεση αλβαιντανυλης για την αγωγη του οξεος πονου
Perrin-Sarrado et al. S-Nitrosothiols as potential therapeutics to induce a mobilizable vascular store of nitric oxide to counteract endothelial dysfunction
BR112017022506A2 (pt) composições compreendendo aminoácidos para uso no tratamento de mucosites em pacientes com neoplasia submetidos a terapia de radiação e / ou quimioterapia
BR112013006404A2 (pt) processo para produzir grânulos, formulação, e, usos dos grânulos e dos aglomerados prensados
BR112015021212A2 (pt) fórmula de nanocompósitos com base de ferro para tratamento rápido e eficiente de anemia ferropriva
BR112021020304A2 (pt) Nano ou micropartícula de proteína, nano ou micropartícula de proteína-lipídio, método para a síntese de uma nano ou micropartícula de proteína, método para a síntese de uma nano ou micropartícula de proteína-lipídio, nano ou micropartícula de proteína para uso e composição farmacêutica
RU2011129309A (ru) Пищевая композиция, содержащая антиоксидант для усиления антивирусного иммунитета у животных-компаньонов
BR102020005627A2 (pt) suplemento bioativo
BR112018070415A2 (pt) composição farmacêutica, kit, inibidor e inibidor para uso

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21770418

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021770418

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021770418

Country of ref document: EP

Effective date: 20221020

NENP Non-entry into the national phase

Ref country code: DE